Almirall and Forest Laboratories have announced that a Phase 3 study of their aclidinium bromide DPI for the treatment of COPD produced significant improvement from baseline in FEV1 at clinical doses but underperformed when compared to placebo. Another Phase 3 double-blind study is still underway, and Forest Lab’s President Lawrence S. Olanoff expressed confidence that the results, which are expected in the first quarter of 2011, will be more in line with the promising results from previous studies. Read the company’s press release.
Disappointing Phase 3 results for aclidinium bromide
published on
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
October 28-October 30: Deutches Aerosol Therapie Symposium (DATS), Marburg, Germany
November 10-November 11: Rescon Europe 2026, Porto, Portugal
